A Randomized Trial of Consolidative Immunotherapy With vs Without Thoracic Radiotherapy and / or Stereotactic Body Radiation Therapy (SBRT) After First-Line Systemic Therapy for Metastatic NSCLC
Latest Information Update: 19 Mar 2025
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 14 Mar 2025 Planned End Date changed from 31 Dec 2027 to 31 Jul 2027.
- 28 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 24 Jun 2020 Planned number of patients changed from 116 to 112.